Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Feb 07, 2012 Support grows for medical-device community -
Dec 19, 2011 BioAccel launches network to attract bio funding
-
Jul 19, 2011 Cardinal Health opens $11M Phoenix facility
-
Apr 07, 2011 Algae Biosciences Corp. taken public
Share on Twitter
Share on Facebook
Email to a friend
Print Article
ImmuneRegen BioSciences reports positive results from influenza study
[Source: Trading Markets] - ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, has reported positive results from a study that evaluated its lead anti-influenza drug, Homspera.
The preclinical study with H5N1 influenza virus, which is highly lethal to humans and animals, revealed that Homspera treatment starting one day following influenza infection dramatically reduced symptoms of influenza infection and increased survival by 60% over infected controls.
For more information: ImmuneRegen BioSciences reports positive results from influenza study
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
